About the Company
inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $INO News
Inovio Pharmaceuticals files patent for method for preparing electroporation device for treatment using charge current
Prepare an electroporation device efficiently with Inovio Pharmaceuticals' patented method. Optimize charging process for treatment delivery.
Inovio Pharmaceuticals Inc INO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Inovio Pharmaceuticals Inc. Q4 Loss Narrows
(RTTNews) - Inovio Pharmaceuticals Inc. (INO) released Loss for fourth quarter that decreased from last year The company's bottom line came in at -$25 million, or -$1.10 per share. This compares ...
Call Traders Swarm Heavily Shorted Pharma Stock
Echoing this, its Schaeffer's put/call open interest ratio (SOIR) sits higher than 97% of annual readings, indicating ...
Q4 2023 Inovio Pharmaceuticals Inc Earnings Call
Thomas Hong; IR; INOVIO Pharmaceuticals, Inc. Jacqueline Shea; President & CEO; INOVIO Pharmaceuticals, Inc. Michael Sumner; Chief Medical Officer; INOVIO ...
INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
INOVIO announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for patients with ...
Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript
Good afternoon, ladies and gentlemen and welcome to the INOVIO Fourth Quarter and Year-End 2023 Financial Results Conference Call. At this time all lines are in a listen-only mode. Following the ...
INO Inovio Pharmaceuticals, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Q4 2023 Inovio Pharmaceuticals Inc Earnings Call
Q4 2023 Inovio Pharmaceuticals Inc Earnings Call Q4 2023 Inovio Pharmaceuticals Inc Earnings Call HOME MAIL NEWS FINANCE SPORT CELEBRITY STYLE WEATHER MORE... Yahoo Finance Sign in Mail Sign in to ...
Inovio Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...